Pazopanib, another multi-kinase inhibitor (VEGFR-1/-2/-3, PDGFRα/β, and c-Kit), is also approved for the treatment of RCC (Majidpoor and Mortezaee, 2021; Liu et al., 2023; Yu et al., 2023). Here, FLT1 is linked to renal cell carcinoma.